Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18+
SponsorUniversiteit Antwerpen

About this trial

The goal of the MYSSELF (Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers) study is to investigate which biological markers (i.e., (epi)genetic biomarkers) found in self-collected samples, such as first-void urine and vaginal samples, are linked to the presence of endometrial, ovarian, vulvar, or vaginal (pre-)cancer or to postmenopausal bleeding. Samples collected by clinicians from the cervix or vulva, as well as blood and tissue samples, will be used for comparison. The study will explore whether these markers could help improve earlier and less invasive detection of gynecological cancers in the future.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Individuals having female genital organs, regardless of their gender identity.

18 years old or older at the time of signing the informed consent form.

Diagnosed with either endometrial, ovarian, vulvar, or vaginal cancer irrespective of stage; diagnosed with one of their precursor lesions; or individuals with postmenopausal bleeding.

Has not started any form of cancer treatment prior to study enrolment.

Disqualifiers

Individuals that underwent hysterectomy or ovariectomy.

Pregnant individuals or 6 weeks post-partum.

Treatment for endometrial, ovarian, vulvar, or vaginal (pre-)cancer in the last 6 months before participation in the study.

Participating in another interventional clinical study (where, e.g., a medical device, drug, or vaccine is evaluated) at the same time as participating in this study. Participation in another observational or low-interventional clinical study at the same time is allowed.

Trial design

Design model

Single group

Treatments tested in this trial

  • Colli-Pee 20 mL device with UCM

    Device

    Participants will collect a first-void urine (the initial part of the urine stream) sample with the 20 mL Colli-Pee device prefilled with urine conservation medium (UCM, DNA Genotek, Canada). This sample can be taken at home the day before or the day of the planned consultation at the hospital or at the hospital itself.

  • Evalyn Brush

    Device

    Participants will collect a vaginal self-sample with the Evalyn Brush (Rovers Medical Devices, The Netherlands) at home the day before or the day of the planned consultation at the hospital or at the hospital itself.

Treatment groups

730 Participants
are divided into 1 treatment group
Group A: Participants Providing Samples for Biomarker AnalysisExperimental treatment 2 interventions

Trial outcomes

Primary outcomes

1

Number and overview of biomarkers associated with the presence of gynecological (pre-)cancers

The primary objective of this study is to determine the feasibility of detecting (epi)genetic biomarkers in participants with (pre-)cancer (endometrial, ovarian, vulvar, or vaginal cancer). This evaluation will be conducted using multiple sample types: self-samples (first-void urine and vaginal samples), clinician-collected cervical/vulvar samples, blood samples, and tissue samples.

Time frame
48 months

Secondary outcomes

1

Comparison of the biomarkers in different sample types

The secondary objective is to compare the presence of biomarkers across different sample types (self-samples (first-void urine and vaginal samples), clinician-collected cervical/vulvar samples, blood samples, and tissue samples).

Time frame
48 months
2

Association of biomarkers and presence of postmenopausal bleeding

The third objective is to explore the association of the identified biomarkers with clinical characteristics in individuals with postmenopausal bleeding, a symptom that can arise from a variety of conditions, including but not limited to endometrial cancer.

Time frame
72 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Universiteit Antwerpen

Lead sponsor

University Hospital, Antwerp

Collaborator